ESTRO 2025 - Abstract Book

S1437

Clinical - Lung

ESTRO 2025

compared surgical techniques (lobectomy and wedge resection) with chemoradiotherapy. The primary endpoint, overall survival (OS), was assessed using Kaplan-Meier analysis and log-rank testing. Multivariate Cox regression was performed to assess the association of selected variables including gender, chemotherapy and age with OS using statistical significance p<0.01. Results: Of the 2,310 included patients, 742 (32.1%) were treated with surgery while 1,568 (67.9%) underwent chemoradiotherapy. Baseline characteristics revealed that non-white race (13.2% vs 8.5%, p=0.007), T2 stage (51.8% vs 33.4%, p <0.001) and chemotherapy (100% vs 56.7%, p<0.001) were more common in the chemoradiotherapy group. Surgery was associated with a longer OS compared to the chemoradiotherapy group (median: OS 51 (95% CI 42.8-59.2) vs. 27 months (95% CI 25.06-28.937), p<0.001); Figure 1 . Multivariate Cox analysis showed that females (HR=0.838 (95% CI 0.771-0.910), p < 0.001) and patients younger than 70 years (HR=0.764 (95% CI 0.703-0.831), p<0.001) had significantly longer OS. Chemotherapy addition to surgery was also associated with a lower mortality hazard (HR=0.705 (95% CI 0.583-0.854), p <0.001) compared to receiving surgery only; Figure 2. Patients who underwent lobectomy (n=466) and wedge resection (n=238) had better OS compared to chemoradiotherapy, with a median survival of 64 months for lobectomy, 31 months for wedge resection, and 27 months for chemoradiotherapy (p< 0.001).